Vaccine News and Research

Latest Vaccine News and Research

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante Pharmaceuticals, Inc. today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).

19 Apr 2011

Idera's gene-silencing oligonucleotide studies published in Journal of Medicinal Chemistry

Idera Pharmaceuticals, Inc. today announced the online publication in the Journal of Medicinal Chemistry of its studies of a novel class of compounds, which we refer to as gene-silencing oligonucleotides.

18 Apr 2011

Biotech Synergy concludes EP-2101 asset transfer, cancer epitopes related portfolio

Biotech Synergy has concluded the asset transfer of multi-epitope cancer vaccine product formerly known as EP-2101 and cancer epitopes related portfolio. Emile Loria, M.D., former President and Chief Business Officer of IDM and former President & CEO of Epimmune, is the founder of Biotech Synergy.

18 Apr 2011

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study.

18 Apr 2011

Virus-sharing draft agreement very close; U.S. yet to formally approve, Reuters reports

A draft agreement that would ensure countries would share virus samples in exchange for access to affordable vaccines derived from such samples in the event of a pandemic is nearly complete, senior diplomats told Reuters on Thursday.

16 Apr 2011

Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting

ImmunoCellular Therapeutics, Ltd., announced that Surasak Phuphanich, MD, Principal Investigator of the Phase I clinical trial of ImmunoCellular's lead dendritic cell cancer vaccine candidate for glioblastoma multiforme presented safety and preliminary efficacy data yesterday at the American Academy of Neurology 63rd Annual Meeting.

16 Apr 2011

Proteins could lead to new therapeutic target for NF2: Wistar Institute researchers

The proteins that provide cells with a sense of personal space could lead to a therapeutic target for Neurofibromatosis Type 2, an inherited cancer disorder, according to researchers at The Wistar Institute. Their findings, which appear in the April 12 issue of the journal Cancer Cell, could have profound implications for NF2 and related cancers, such as mesothelioma.

16 Apr 2011

FEN1 enzyme might serve as anti-cancer therapy target

An enzyme essential for DNA replication and repair in humans works in a way that might be exploited as anti-cancer therapy, say researchers at The Scripps Research Institute and Lawrence Berkeley National Laboratory.

15 Apr 2011

WHO group hopes to have virus-sharing draft agreement finalized by Friday

Countries are narrowing in on a "deal to speed up their response to the next flu pandemic by sharing virus samples in return for access to affordable vaccines," co-chairs of a WHO working group told reporters on Tuesday, Reuters reports.

15 Apr 2011

Safer-sex education leads to fewer episodes of unprotected sex

Teaching young women how to prevent sexually transmitted infections (STIs) increases condom use and might reduce their number of sexual partners, but little research exists on whether educational programs reduce rates of STIs such as human papillomavirus, according to an updated research review from England.

15 Apr 2011

New JAMA issue focuses on infectious diseases and immunology

Several media outlets report on findings published in this week's issue of JAMA, which focuses on infectious diseases and immunology.

15 Apr 2011

African genital herpes strains are more infectious than the U.S. virus

Strains of genital herpes in Africa are far more virulent than those in the United States, researchers at Harvard Medical School report, a striking insight into a common disease with important implications for preventing HIV transmission in a region staggered by the HIV/AIDS epidemic.

15 Apr 2011

Quest PharmaTech, Hemispherx Biopharma enter clinical development arrangement

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.

15 Apr 2011

Novartis, Duke sign deal to develop pandemic flu vaccine

The Duke Human Vaccine Institute today announced a collaboration and strategic agreement with Novartis Vaccines and Diagnostics to enable the rapid development of a vaccine and accelerate preparedness in case of a pandemic virus threat such as pandemic influenza.

15 Apr 2011

The Wistar Institute, Advaxis enter research collaboration

Advaxis, Inc., the live, attenuated Listeria monocytogenes vaccine company, has entered into a research collaboration with the laboratory of Ellen Puré, Ph.D., professor/associate vice president for Academic Affairs at The Wistar Institute.

15 Apr 2011

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

A novel brain tumor vaccine clinical trial study demonstrates a longer survival time in patients with glioblastoma, according to findings being presented at the 79th Annual Scientific Meeting of the American Association of Neurological Surgeons in Denver.

12 Apr 2011

Scientists develop new method to detect virus presence in cells

Scientists at the Naval Research Laboratory Center for Bio-Molecular Science and Engineering have developed a method to detect the presence of viruses in cells and to study their growth.

12 Apr 2011

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant from the National Cancer Institute under the agency's Streamlined Non-competing Award Procedures.

11 Apr 2011

GeoVax Labs expands its HIV/AIDS vaccine program with NIAID, NIH and HVTN

GeoVax Labs, Inc., announced today that it is expanding its preventative HIV/AIDS vaccine development effort in collaboration with the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health and the HIV Vaccine Trials Network.

11 Apr 2011

CINJ experts to comment on vaccine therapy and biomedical informatics

April marks National Cancer Control Awareness Month, which focuses on the importance of prevention, treatment, and research. Making significant contributions in all of these areas is The Cancer Institute of New Jersey, one of the nation's 40 Comprehensive Cancer Centers as designated by the National Cancer Institute and the only such center in New Jersey.

11 Apr 2011